

DAFTAR PUSTAKA

1. Hoorbakht, H. and Bagherkashi, F., 2012. Optic neuritis, its differential diagnosis and management. *Open Ophthalmol J*, 6(1).
2. Wilhelm, H., Schabet, M. 2015. The diagnosis and treatment of optic neuritis. *Dtsch Arztebl Int*, 112(37),616.
3. Pau, D., Al Zubidi, N., Yalamanchili, S., Plant, G.T. and Lee, A.G., 2011. Optic neuritis. *Eye*, 25(7), pp.833-842.
4. Leat SJ, Woo GC (1997) The validity of current clinical tests of contrast sensitivity and their ability to predict reading speed in low vision. *Eye* 11:893–899
5. Wingerchuk,D.M.,Lennon,V.A.,Pittock,S.J.,etal.,2006.Reviseddiagnosticcriteri for neuromyelitisoptica.*Neurology*66(10),1485–1489.
6. Katz, B., 1995. The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. *Trans Am Ophthalmol Soc*, 93, p.685.
7. Dain SJ, Rammohan KW, Benes SC, King-Smith PE (1990) Chromatic, spatial, and temporal losses of sensitivity in multiple sclerosis. *Invest Ophthalmol Vis Sci* 31:548–558
8. Silverman, S.E., Hart, W.M., Gordon, M.O. and Kilo, C., 1990. The dyschromatopsia of optic neuritis is determined in part by the foveal/perifoveal distribution of visual field damage. *Invest Ophthalmol Vis Sci*, 31(9), pp.1895-1902.
9. Keltner, J. L., Johnson, C. A., Spurr, J. O., & Beck, R. W. (1993). Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. *Arch Ophthalmol*, 111(2), 231-234.
10. American Optometric Association. *Comprehensive Eye and Vision Examination*. ST. Louis: AOA, 2018.
11. Mayo Foundation for Medical Education and Research. *Optic Neuritis*. Rochester: Mayo Clinic. 2018
12. Menon, V., et al. 2011. Management of Optic Neuritis. *Indian J Ophtalmol*, 59(2)117



13. Mäntyjärvi, M. and Laitinen, T., 2001. Normal values for the Pelli-Robson contrast sensitivity test. *J Cataract Refract Surg*, 27(2), pp.261-266.